Vaginal Squamous Intraepithelial Lesions
Vaginal intraepithelial neoplasia (VaIN) affects 0.2 per 100,000 women in the United States. VaIN, like cervical intraepithelial neoplasia (CIN), is caused by Human Papilloma Virus (HPV). High-risk HPV (hrHPV) positivity has been reported in 99% of VaIN 1 and 90-96% of VaIN 2/3 lesions. As in other HPV-mediated lower genital tract neoplasias, VaIN 1 represents a transient, productive viral infection. By comparison, VaIN 2/3 lesions are truly precancerous. These high-grade neoplasias represent lesions where HPV has disrupted the cell cycle causing proliferation of undifferentiated cells that if persistent carry a significant risk of malignant transformation.
New terminology (Lower Anogenital Squamous Terminology, LAST) reflects this biologic difference, and is intended for use across all lower genital tract neoplasias regardless of sex of the individual or site of the lesion. Transient viral lesions (VaIN 1) are termed vaginal low grade squamous intraepithelial lesions (LSIL) and precancerous lesions (VaIN 2/3) are termed vaginal high grade squamous intraepithelial lesions (HSIL).
There are no recommendations to screen low risk women for VaIN. Women who have had a hysterectomy for benign conditions with no prior history of HSIL do not require further screening.
Current management recommendations rely on expert opinion and retrospective studies. Women with LSIL should not undergo immediate treatment and should be managed expectantly. After a single LSIL cytologic result, women should be rescreened in 1 year with either cytology alone or co-testing. If cytology is persistently positive for two years, or co-testing positive one year later, she should under vaginal colposcopy. At subsequent follow-up exams, if a woman with no prior history of HSIL has a negative co-test, no further screening is recommended. Women with persistent and stable LSIL beyond 2 years can have their follow-up interval extended to every 2-3 years. Women with persistent LSIL beyond 2 years may also undergo treatment as an acceptable alternative.
Any woman with HSIL should be treated given its malignant potential. Treatment can include excision, ablation, or medical therapy. There is no data to suggest that any single treatment is superior. Complications of treatment include pain, irritation, scarring, and sexual dysfunction. Treatment decisions should be individualized based on a woman’s prior treatment, the presence of multifocal disease, other medical comorbidities, and desire to preserve sexual function. Invasive disease must be excluded prior to medical or ablative therapies. Ablative therapies include CO2 laser and ultrasonic surgical aspiration. These therapies are well tolerated, with low incidences of postoperative pain or scarring. The most common topical therapies include 5% imiquimod or 5-fluorouracil. Side effects of topical therapies include local burning and soreness that does not result in treatment disruption or interfere with usual activities. Excisional treatments are associated with higher risks of sexual dysfunction, persistent pain, and scarring. Following treatment, women require long term follow-up with annual cytologic screening or every 2-3 years co-testing, once initial follow-up is negative.
Khan MJ, Massad LS, Kinney W, et al. A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol. 2016 May;141(2):364-370. doi: 10.1016/j.ygyno.2015.11.023. Epub 2016 Feb 22.
Darragh TM, Colgan TJ, Cox JT et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012 Oct;136(10):1266-97. Epub 2012 Jun 28.
Gurumurthy M, Cruickshank ME. Management of vaginal intraepithelial neoplasia. J Low Genit Tract Dis. 2012 Jul;16(3):306-12. doi: 10.1097/LGT.0b013e31823da7fb.
Initial approval March 2018. Revised November 2019
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2019 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.
Back to Search Results